The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1b/2, dose-escalation, randomized, multicenter study of maintenance (maint) ivaltinostat (ival) plus capecitabine (cap) or capecitabine monotherapy in patients (pts) with metastatic pancreatic adenocarcinoma (PDAC) whose disease has not progressed on first-line FOLFIRINOX chemotherapy (CT).
 
Evan Justin Walker
No Relationships to Disclose
 
Erkut Hasan Borazanci
Consulting or Advisory Role - BioNTech; Boehler Life Science Advice; Imaging Endpoints; NanOlogy; Vivacitas Oncology
Speakers' Bureau - Ipsen
Research Funding - BioNTech (Inst); Bristol-Myers Squibb (Inst); Corcept Therapeutics (Inst); Daiichi Sankyo (Inst); Helix BioPharma (Inst); Idera (Inst); Lilly (Inst); Merck (Inst); Minneamrita Therapeutics (Inst); Pharmacyclics (Inst); Samumed (Inst)
 
Gehan Botrus
No Relationships to Disclose
 
Christos Fountzilas
Research Funding - Aravive (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb/Ono Pharmaceutical (Inst); Corcept Therapeutics (Inst); Dragonfly Therapeutics (Inst); ERYTECH Pharma (Inst); Incyte (Inst); Ipsen (Inst); Kadmon (Inst); Kinex (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Rafael Pharmaceuticals (Inst); Seagen (Inst); Syndax (Inst); Taiho Oncology (Inst)
 
J. Randolph Hecht
Stock and Other Ownership Interests - Actym Therapeutics; Rafael Pharmaceuticals
Consulting or Advisory Role - Astellas Pharma; Corcept Therapeutics; Exelixis; Gilead Sciences; Gritstone Bio; Istari; Notch Therapeutics; Regenacy Pharmaceuticals; Tempus
Research Funding - Amgen (Inst); ARMO BioSciences (Inst); Astellas Pharma (Inst); Bold Therapeutics (Inst); Gritstone Bio (Inst); Lilly (Inst); Merck (Inst); Tesaro/GSK (Inst); Tizona Therapeutics, Inc. (Inst); Tizona Therapeutics, Inc. (Inst)
Travel, Accommodations, Expenses - Amgen
 
Anup Kasi
Honoraria - OncLive
Research Funding - Astellas Pharma (Inst); Bavarian Nordic (Inst); Cardiff Oncology (Inst); FibroGen (Inst); Geistlich Pharma (Inst); Halozyme (Inst); Novocure (Inst); Rafael Pharmaceuticals (Inst); TESARO (Inst)
Travel, Accommodations, Expenses - Halozyme; Rafael Pharmaceuticals
 
Niharika B. Mettu
Research Funding - Amgen (Inst); Amphivena (Inst); ARMO BioSciences/Lilly; AstraZeneca/MedImmune; BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); ERYTECH Pharma; Genentech (Inst); Incyte (Inst); Lucence Diagnostics (Inst); Merck; Mereo BioPharma; OncoMed; Repare Therapeutics (Inst); Revolution Medicines; Syros Pharmaceuticals
 
Shubham Pant
Honoraria - 4D Pharma
Consulting or Advisory Role - Ipsen; Xencor; Zymeworks
Research Funding - 4D Pharma (Inst); Arcus Biosciences (Inst); ArQule (Inst); Astellas Pharma (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Elicio Therapeutics (Inst); Five Prime Therapeutics (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); Mirati Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Onco Response (Inst); Purple Biotech (Inst); RedHill Biopharma (Inst); Rgenix (Inst); Sanofi/Aventis (Inst); Xencor (Inst)
 
Glenn Michelson
Employment - CG Pharmaceuticals
Stock and Other Ownership Interests - CG Pharmaceuticals
 
Gene Cho
Employment - CG Pharmaceuticals (I); CrystalGenomics (I)
Leadership - CrystalGenomics (I)
Stock and Other Ownership Interests - Aptose Biosciences; CrystalGenomics (I)
Consulting or Advisory Role - CG Pharmaceuticals
 
Sangsook Ahn Cho
Employment - CG Pharmaceuticals
Leadership - CG Pharmaceuticals
Stock and Other Ownership Interests - CG Pharmaceuticals
 
Lorna Liganor
Employment - CG Pharmaceuticals
 
Andrew H. Ko
Honoraria - BioAscent; Clinical Care Options; Medscape; PER; PlatformQ Health; Research to Practice
Consulting or Advisory Role - ERYTECH Pharma; Five Prime Therapeutics; Gritstone Bio; Imugene; Ipsen; Roche/Genentech; Signatera; SynCoreBio; Syros Pharmaceuticals; Turning Point Therapeutics; Tyme
Speakers' Bureau - Clinical Care Options
Research Funding - AbGenomics International (Inst); Apexigen (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); Leap Therapeutics (Inst); Merck (Inst)